Cologne, Germany, October 2, 2008 /b3c newswire / - CEVEC Pharmaceuticals, a biopharmaceutical company specializing in the development of complex therapeutic proteins using their proprietary human cell expression systems, appointed Rainer Lichtenberger Ph.D., MBA as the new Chief Executive Officer (CEO). Rainer Lichtenberger will replace Prof. Stefan Kochanek, one of the founders of the company, who led the company as interim CEO for nearly half a year and will continue to serve as one of the advisory board members

With Dr. Lichtenberger, CEVEC has attracted a seasoned life science manager with 20 years of management experience in renowned companies such as the Merckle/ratiopharm group and Merck KGaA. There he held various positions of increasing responsibility, among them vice-president of strategic marketing and corporate vice-president of business development. Most recently, he led a private venture-financed German biopharmaceutical development company, where he managed a major series A venture round. Dr. Lichtenberger’s team at CEVEC will be complemented by other experienced staff such as Dr. Christoph Volpers, Chief Operating Officer (COO) and Chief Scientific Officer (CSO) Dr. Gudrun Schiedner.

Gangolf Ehlen, Investment Manager for Venture Capital Investments of Sparkasse KölnBonn and chairman of the advisory board of CEVEC comments: "We are very satisfied that we could win Dr. Lichtenberger as a senior expert with broad and deep industry experience and excellent business networks. We see this as further proof of the attractiveness of CEVEC's unique technology platform. We would like to thank Prof. Kochanek for his commitment in this transition period of the company." Prof. Kochanek said: "I am looking forward to working with Dr. Lichtenberger, whose background in drug development, business development and experience in a venture financed life science company fits perfectly into CEVEC’s ambitious business objectives for the next few years.>
About CEVEC Pharmaceuticals GmbH:
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns. CEVEC’s novel proprietary and patent-protected human CAP and PIOS expression systems are ideal for manufacturing complex biopharmaceutical molecules, which were previously unavailable or could only be extracted from plasma or tissue. Covering all steps from the isolation of primary human cells to establishing specific production cell lines, CEVEC strictly adheres to the latest quality and regulatory standards required for therapeutics. CEVEC is successfully using its proprietary human CAP expression technology to develop several of its innovative biopharmaceutical molecules up to the preclinical phase and aims to out-license these through partnerships with renowned pharmaceutical companies for further product development and commercialization.

Further information on CEVEC Pharmaceuticals GmbH:
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 62
D-51105 Köln, Germany
phone: +49 221-46020800
fax: +49 221-46020801
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.